We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+85.72%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.26B
AUM Growth
-$73.2M
Cap. Flow
-$340M
Cap. Flow %
-27.05%
Top 10 Hldgs %
36.58%
Holding
220
New
69
Increased
26
Reduced
46
Closed
56

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$13.6M
2
GOSS icon
Gossamer Bio
GOSS
+$8.85M
3
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$7.61M
4
CLDX icon
Celldex Therapeutics
CLDX
+$7.3M
5
BDTX icon
Black Diamond Therapeutics
BDTX
+$6.53M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$23.1M
2
BTAI icon
BioXcel Therapeutics
BTAI
+$17.3M
3
IMVT icon
Immunovant
IMVT
+$12M
4
ARGX icon
argenx
ARGX
+$11.4M
5
VSTM icon
Verastem
VSTM
+$7.36M

Sector Composition

Rank Sector Weight
1 Healthcare 25.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CHMA
51
DELISTED
Chiasma, Inc. Common Stock
CHMA
$7.69M 0.61%
1,429,633
-645,859
-31% -$3.56M
ZYME icon
52
PUT
Zymeworks
ZYME
$1.67B
$7.68M 0.61%
+212,800
New +$7.84M
KURA icon
53
Kura Oncology
KURA
$826M
$7.59M 0.6%
465,619
-294,184
-39% -$4.24M
ADVM
54
CALL
DELISTED
Adverum Biotechnologies
ADVM
$7.49M 0.6%
35,870
+13,430
+60% +$2.38M
BDTX icon
55
Black Diamond Therapeutics
BDTX
$98.6M
$7.49M 0.6%
+177,544
New +$6.53M
ICPT
56
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$7.19M 0.57%
150,000
+100,000
+200% +$7.73M
IMVT icon
57
Immunovant
IMVT
$8.11B
$6.87M 0.55%
282,163
-560,300
-67% -$12M
GBT
58
PUT
DELISTED
Global Blood Therapeutics, Inc.
GBT
$6.45M 0.51%
+102,100
New +$7M
BLUE
59
DELISTED
bluebird bio
BLUE
$6.4M 0.51%
8,096
+7,594
+1,513% +$5.73M
DCPH
60
PUT
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$5.97M 0.48%
+100,000
New +$5.35M
RARE icon
61
CALL
Ultragenyx Pharmaceutical
RARE
$2.56B
$5.75M 0.46%
73,500
-26,500
-27% -$1.75M
CBAY
62
DELISTED
Cymabay Therapeutics
CBAY
$5.34M 0.42%
1,529,830
-837,020
-35% -$2.42M
AUPH icon
63
Aurinia Pharmaceuticals
AUPH
$1.93B
$5.33M 0.42%
327,771
+109,000
+50% +$1.75M
ARVN icon
64
PUT
Arvinas
ARVN
$536M
$5.17M 0.41%
+154,000
New +$6.54M
KDMN
65
DELISTED
Kadmon Holdings, Inc.
KDMN
$5.02M 0.4%
981,070
-335,776
-25% -$1.51M
TCDA
66
DELISTED
Tricida, Inc. Common Stock
TCDA
$4.86M 0.39%
177,002
-2,798
-2% -$76.2K
MDGL icon
67
Madrigal Pharmaceuticals
MDGL
$11.4B
$4.82M 0.38%
42,554
+2,220
+6% +$218K
EIDX
68
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$4.77M 0.38%
+100,000
New +$4.65M
TVRD
69
Tvardi Therapeutics
TVRD
$19.7M
$4.68M 0.37%
7,598
-7,740
-50% -$4.27M
BMRN icon
70
CALL
BioMarin Pharmaceuticals
BMRN
$11.7B
$4.65M 0.37%
+37,700
New +$3.75M
PCVX icon
71
Vaxcyte
PCVX
$8.08B
$4.42M 0.35%
+139,813
New +$4.5M
CHAQ.U
72
DELISTED
Chardan Healthcare Acquisition 2 Corp. Units, each consisting of one share of Common Stock, and one
CHAQ.U
$4.2M 0.33%
+400,000
New +$4.02M
BMY.RT
73
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$3.94M 0.31%
1,100,000
+150,000
+16% +$541K
AVDL
74
DELISTED
Avadel Pharmaceuticals
AVDL
$3.94M 0.31%
487,143
+405,000
+493% +$3.57M
OTIC
75
DELISTED
Otonomy, Inc.
OTIC
$3.86M 0.31%
1,067,271
-300,000
-22% -$781K
1 2
3
4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2020 Portfolio in Review

As of Q2 2020, Ikarian Capital held 220 positions worth $1.26B, down 5.5% from $1.33B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Ikarian Capital withdrew a net $340M in Q2 2020, closing 56 positions and reducing 46 holdings. Its most notable exit was Acceleron Pharma, an estimated $23.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 20% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Blueprint Medicines worth $15.7M.

  • Ikarian Capital's largest Q2 2020 buy was Blueprint Medicines: 201,662 shares worth $15.7M.
  • Ikarian Capital added most to bluebird bio in Q2 2020, an estimated $5.73M increase.
  • Ikarian Capital's biggest Q2 2020 reduction was BioXcel Therapeutics, cutting an estimated $17.3M.
  • Ikarian Capital fully exited Acceleron Pharma in Q2 2020, selling an estimated $23.1M.
  • Ikarian Capital's ten largest holdings make up 37% of its $1.26B portfolio in Q2 2020.
  • Ikarian Capital opened 69 new positions and closed 56 in Q2 2020.
  • Ikarian Capital's portfolio value fell 5.5% quarter-over-quarter to $1.26B.

Based on Ikarian Capital's 13F filing for Q2 2020, filed 14 Aug 2020.